Activation of the contact system in cerebrospinal fluid of patients with Alzheimer disease

Alzheimer Disease and Associated Disorders

Volumn 12, Issue 2, 1998, Pages 102-108

  Bergamaschini, Luigi ^a,d   Parnetti, Lucilla ^b   Pareyson, Davide ^c   Canziani, Stefania ^a   Cugno, Massimo ^a   Agostoni, Angelo ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b UNIVERSITY OF PERUGIA   (Italy)

^c DEPARTMENT OF NEUROSURGERY   (Italy)

^d FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

Author keywords

Contact system; Factor XII; High molecular weight kininogen; Inflammation; Kallikrein; Amyloid

Indexed keywords

AMYLOID BETA PROTEIN; BLOOD CLOTTING FACTOR 12; HIGH MOLECULAR WEIGHT KININOGEN; KALLIKREIN;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; CEREBROSPINAL FLUID; CLINICAL ARTICLE; COMPLEMENT ACTIVATION; CONTROLLED STUDY; DEMYELINATING DISEASE; ENCEPHALITIS; FEMALE; HUMAN; HUMAN TISSUE; INFLAMMATORY DISEASE; KALLIKREIN KININ SYSTEM; MALE; MULTIPLE SCLEROSIS; NEUROTOXICITY; PATHOGENESIS; POLYNEUROPATHY; PRIORITY JOURNAL;

EID: 0032450703     PISSN: 08930341     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002093-199806000-00008     Document Type: Article

References (53)

1. Abraham CR, Selkoe DJ, Potter H. Immunochemical identification of the serine protease inhibitor, α1-antichymotrypsin in the brain amyloid deposits of Alzheimer's disease. Cell 1988;52:487-01.
2. Aisen PS, Davis KL. Inflammatory mechanism in Alzheimer's disease: implications for therapy. Am J Psychiatry 1994;151:1105-13.
3. Akiyama H, Ikeda K, Kondo H, McGeer PL. Thrombin accumulation in brains of patients with Alzheimer's disease. Neurosci Lett 1992;146:152-4.
4. Aoyagi T, Wada T, Nagai M, et al. Deficiency of kallikrein-like enzyme activities in cerebral tissue of patients with Alzheimer's disease. Experientia 1990;46:94-7.
5. 2-macroglobulin indicate an acute-phase state in Alzheimer's disease cortices. FEBS Lett 1991;285:111-4.
6. Berrettini M, Lammle B, White T, Curd J, Griffin JH. Detection of in vivo cleavage of high molecular weight kininogen in human plasma by immunoblotting with monoclonal antibodies. Blood 1986;68:455-62.
7. Bhoola KD, Figueroa CD, Worthy K. Bioregulation of kinins: kallikreins, kininogens, and kininases. Pharmacol Rev 1992;44:1-80.
8. Burdick D, Soreghan B, Kwon M, et al. Assembly and aggregation properties of synthetic Alzheimer's A4/β amyloid peptide analogs. J Biol Chem 1992;267:546-54.
9. Choi-Miura NH, Ihara Y, Fukuchi K, et al. SP-40 is a constituent of Alzheimer's amyloid. Acta Neuropathol 1992;83:260-4.
10. de Agostini A, Lijnen HR, Pixley RA, Colman RW, Schapira M. Inactivation of Factor XII active fragment in normal plasma. Predominant role of C1-inhibitor. J Clin Invest 1984;73:1542-49.
11. DeLa Cadena RA, Wachtfogel YT, Colman RW. Contact activation pathway: inflammation and coagulation. In: Colman RW, Hirsh J, Marder VJ, Salzman EW, eds. Hemostasis and thrombosis: basic principles and clinical practice, 3rd ed. Philadelphia: J.B. Lippincott, 1994:219-40.
12. Dihanich M, Kaser M, Reinhard E, Cunningham D, Monard D. Prothrombin mrnA is expressed by cells of the nervous system. Neuron 1991;6:575-81.
13. Eikelenboom P, Stam FC. Immunoglobulins and complement factors in senile plaques: an immunohistochemical study Acta Neuropathol 1982;57:239-42.
14. Eikelenboom P, Hack CE, Rozemuller JM, Stam FC. Complement activation in amyloid plaques in Alzheimer's dementia. Virchows Arch (B) 1989;56:259-62.
15. Eikelenboom P, Rozemuller JM, Kraal G, et al. Cerebral amyloid plaques in Alzheimer's disease but not in scrapie-affected mice are closely associated with a local inflammatory process. Virchows Arch (B) 1991; 60:329-36.
16. Folstein M, Folstein S, McHugh P. Mini-mental state. J Psychiatr Res 1975;12:189-98.
17. Gigli I, Mason JM, Colman RW, Austen KF. Interaction of plasma kallikrein with C1-inhibitor. J Immunol 1970;504:574-81.
18. Harpel PC, Cooper NR. Studies on human plasma C1-inactivator-enzime interactions. I. Mechanism of interaction with C1s, plasmin and trypsin. J Clin Invest 1975;55:593-604.
19. Ishii T, Haga S, Kametani F. Presence of immunoglobulins and complement in the brain of patients with Alzheimer's disease. In: Pouplard-Berthelaix A, Emile J, Christen J, eds. Immunology and Alzheimer's disease. New York: Springer-Verlag, 1988:7-17.
20. Itagaki S, Akiyama H, Saito H, McGeer PL. Ultrastructural localization of complement membrane attack complex (MAC)-like immunoreactivity in brains of patients with Alzheimer's disease. Brain Res 1994;645:78-84.
21. Jiang H, Burdick D, Glabe CG, Cotman CW, Tenner AJ. β-amyloid activates complement by binding to a specific region of the collagen-like domain of the C1q A chain. J Immunol 1994;152:5050-9.
22. Johnson SA, Lampert-Etchels M, Rozowsky I, Pasinetti GM, Finch CE. Complement mRNA in the mammalian brain: response to Alzheimer's disease and experimental brain lesioning. Neurobiol Aging 1992;13:641-8.
23. Kalaria RN, Perry G. Amyloid P component and other acute-phase proteins associated with cerebellar Aβ-deposits in Alzheimer's disease. Brain Res 1993;631:151-5.
24. Kettner C, Shaw E. Inactivation of trypsin-like enzymes with peptides of arginine chlorometyl ketone. Methods Enzymol 1981;80:826-42.
25. Kingston IB, Castro MJM, Anderson S. In vitro stimulation of tissue-type plasminogen activator by Alzheimer amyloid β-peptide analogues. Nature Med 1995;1:138-42.
26. Klegeris A, Walker DG, McGeer PL. Activation of macrophages by Alzheimer β-amyloid peptide. Biochem Biophys Res Commun 1994; 199:984-91.
27. Kleniewsky J, Blankenship DT, Cardin AD, Donaldson V. Mechanism of enhanced kinin release from high molecular weight kininogen by plasma kallikrein after exposure to plasmin. J Lab Clin Med 1992;120:129-39.
28. Kovacs DM, Hillary JF, Page KJ, et al. Alzheimer-associated presenilins 1 and 2: neuronal expression in brain and localization to intracellular membranes in mammalian cells. Nature Med 1996;2:224-9.
29. Lammle B, Berrertini M, Griffin JH. Immunoblotting studies of coagulation Factor XII, plasma prekallikrein and high molecular weight kininogen. Sem Throm Hemost 1987;13:106-14.
30. McComb RD, Miller KA, Carson SD. Tissue factor antigen in senile plaques of Alzheimer's disease. Am J Pathol 1991;139:491-4.
31. McGeer PL, Akiyama H, Itagaki S, McGeer EG. Activation of the classical complement pathway in brain tissue of Alzheimer patients. Neurosci Lett 1989a;107:341-6.
32. McGeer PL, Akiyama H, Itagaki S, McGeer EG. Immune system response in Alzheimer's disease. Can J Neurol Sci 1989b;16:516-27.
33. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA work group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984;34:939-44.
34. Nuijens JH, Huijbregts CCM, Eerenberg-Belmer AJM, et al. Quantification of plasma factor XII-C1 inhibitor and kallikrein-C1 inhibitor complexes in sepsis. Blood 1988;72:1841-8.
35. Patson PA, Gettins P, Beechem J, Shapira M. Mechanism of serpin action: evidence that C1 inhibitor functions as a suicide substrate. Biochemistry 1991;30:8876-82.
36. Ratnoff OD, Pensky J, Ogston D, Naff GB. The inhibition of plasmin, plasma kallikrein, plasma permeability factor, and the C1'r subcomponent of the first component of complement by serum C1' esterase inhibitor. J Exp Med 1969;129:315-31.
37. Reisberg G, Ferris S, DeLeon M, Crooke T. The global deterioration scale for assessment of primary degenerative dementia. Am J Psychiatry 1982;139:1136-9.
38. Rogers J, Cooper NR, Webster S, et al. Complement activation by β-amyloid in Alzheimer's disease. Proc Natl Acad Sci USA 1992;89:10016-20.
39. Schreiber AD, Kaplan AP, Austen KF. Inhibition by C1-INH of Hageman factor fragment activation of coagulation, fibrinolysis, and kinin generation. J Clin Invest 1973;52:1402-9.
40. Selkoe DJ. The molecular pathology of Alzheimer's disease. Neuron 1991;6:487-98.
41. Selkoe DJ. Cell biology of the amyloid β-protein precursor and the mechanism of Alzheimer's disease. Annu Rev Cell Biol 1994;10:373-03.
42. Smith MD, Cribbs DH, Tenner AJ, et al. Decreased levels of C1q in cerebrospinal fluid of living Alzheimer's patients correlate with disease state. Neurobiol Aging 1994;15:609-14.
43. Styren SD, Civin VH, Rogers J. Molecular, cellular, and pathologic characterization of HLA-DR immunereactivity in normal elderly and Alzheimer's disease brain. Exp Neurol 1990;10:93-104.
44. Thomas T, Thomas G, McLendon C, Sutton T, Mullan M. β-amyloid-mediated vasoactivity and vascular endothelial damage. Nature 1996;80:168-71.
45. Tomlinson BE, Blessed G, Roth M. Observations on the brains of demented old people. J Neurol Sci 1970;11:205-42.
46. Veerhuis R, van der Valk P, Janssen I, Zhan SS, Van Nostrand WE, Eikelenboom P. Complement activation in amyloid plaques in Alzheimer's disease brains does not proceed further than C3. Virchows Arch 1995;6:603-10.
47. Veerhuis R, Janssen I, Hack CE, Eikelenboom P. Early complement components in Alzheimer's disease brain. Acta Neuropathol 1996;91:53-60.
48. Walker DG, McGeer PL. Complement expression in neuroblastoma and astrocytoma cell lines of human origin. Neurosci Lett 1993;157: 99-102.
49. Walker DG, Yasuhara O, Patston PA, McGeer EG, McGeer PL. Complement C1-inhibitor is produced by brain and is cleaved in Alzheimer's disease. Brain Res 1995;675:75-82.
50. Yanker BA, Duffy LK, Kirschner A. Neutrophic and neurotoxic effects of amyloid β protein: reversal by tachykinin neuropeptides. Science 1990;250:279-82.
51. Yasuhara O, Walker DG, McGeer PL. Hageman factor and its binding sites are present in senile plaques of Alzheimer disease. Brain Res 1994;654:234-40.
52. Zhan SS, Veerhuis R, Janssen I, Kamphorst W, Eikelenboom P. Immunohistochemical distribution of the inhibitors of the terminal complement complex in Alzheimer's disease. Neurodegeneration 1994;3: 111-7.
53. Ziccardi RJ, Cooper NR. Active disasssembly of the first complement component C1 by C1-inactivator. J Immunol 1979;123:788-92.